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Beneath most lively policy debates sit dry-as-dust theoretical
and methodological discussions. Current disputes over the
EU Adaptive Pathways initiative1,2 and the proposed US 21st
Century Cures Act3 may ultimately rest on addressing arcane
issues of data curation, standardization, and utilization.
Improved extraction of information on the safety and effec-
tiveness of drugs-in-use must parallel adjustments in evidence
requirements at the time of licensing. To do otherwise may
compromise safety and efﬁcacy in the name of fostering
innovation.
To take stock of the current state of the art, this essay identiﬁes
sources of demand for better utilization of real-world medical
data, highlights the need for improved data quality, data access,
and analytic methods, and evaluates the US Sentinel Initiative
and Optum Labs as examples of distributed and centralized data
initiatives.
To engage with emerging needs, this essay offers an integrated
research and policy agenda. Academic research topics focus on
improving data quality and access and on developing hybrid
observational and interventionist methods to enhance causal
inference under less-than-ideal conditions. Policy agendas focus
on the need for international coordination on data access, data
standards, and evidentiary thresholds.
DEMAND FOR BETTER UTILIZATION OF MEDICAL DATA
Three trends are now driving demand for improved extraction of
information on the safety and effectiveness of drugs from clinical
trials data, registries, claims data, and health records.4 These
include: 1) increasing pressures to accelerate access for patients in
need of new and better treatments for a wider range of medical
conditions; 2) splintering of indications into smaller treatment
groups as a consequence of advances in genetics and in transla-
tional and “precision medicine”; 3) growing demands from payers
and health technology assessment ofﬁcials for quantiﬁable meas-
ures of relative effectiveness of new drugs. Deﬁning the path for-
ward requires an understanding of each of these trends, and how
they are shaping the evolution of evidence requirements.
First, with the advent of adaptive approaches to drug licensing,
the need to leverage observational data to reassess licensing deci-
sions is expanding from a few drugs that target life-threatening
unmet needs to many drugs addressing a wider variety of medical
needs.5 Calls for rapid access to new treatments originally came
from advocates for patients with fast-progressing conditions such
as HIV, cancer, and many orphan conditions. Patients with
chronic, slowly progressing diseases with unsatisfactory treatment
options are now making the same plea for rapid access. The EU
Adaptive Pathways initiative and the US 21st Century Cures ini-
tiative both seek to address patients’ demands for early access to a
broadening array of treatments, with an associated need for reas-
sessment of initial licensing decisions in light of evolving real-
world evidence (RWE) on drug safety and effectiveness.
For these initiatives to succeed, regulators must strike an
appropriate balance between addressing needs through early
access to a drug and accepting uncertainty on the safety, efﬁcacy,
and effectiveness of a drug. The issue is the extent to which
uncertainties must be resolved at the time of initial licensing and
coverage decisions or whether positive decisions may be based on
the balance of acceptable uncertainty at the time of licensing
with continuous monitoring after initial licensing. Both Adaptive
Pathways and 21st Century Cures initiatives are designed to fos-
ter the progressive reduction of uncertainty through pre-agreed
evidence generation plans, with restrictions on initial utilization,
and monitoring in the marketplace. Should emerging evidence
suggest that the beneﬁt–risk trade-offs are not acceptable,
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regulators should be legally authorized and politically empowered
to restrict or withdraw a product even in the face of resistance
from patients and sponsors. Together, these postlicensing compo-
nents of these initiatives should improve the beneﬁt–risk trade-
offs for patients relative to current approaches. These critical
components at the back end of Adaptive Pathways and 21st Cen-
tury Cures initiatives require improved postmarketing evidence
generation and utilization.
Second, the recognition of population heterogeneity and the
complexity of treatment effects has resulted in the splintering of
indications and treatment groups. Precision medicines are directed
at subpopulations deﬁned by genotypic and phenotypic markers,
with disease stratiﬁcations based on genotypic biomarkers accom-
panied by dedicated diagnostics. Acquiring subgroup-speciﬁc infor-
mation on real-world beneﬁts and risks will require improved
postmarketing evidence generation and utilization.
With narrower deﬁnitions of indications, the recruitment of
sufﬁcient numbers of confounder-cleansed subjects for random-
ized controlled trials (RCTs) is becoming increasingly difﬁcult.
Conventional RCTs will be feasible for some identiﬁable sub-
groups with common mutations, but will not be feasible for rare
mutations. For less common biomarkers, beneﬁt–risk informa-
tion based on real-world data accrued later in the lifespan of a
product may be needed. Moreover, as more biomarkers are iden-
tiﬁed the trend is towards custom-made medicines. As patients
receive individualized gene therapies based on modiﬁed patient-
derived cells, antisense oligonucleotides, and other types of
advanced therapies, treatment-eligible populations approach the
limit of n 5 1. What might be termed “basket licensing” of a
family of medicines with individual variations may be the only
viable route to market. However, even minor changes in the
molecular structure of a drug could result in signiﬁcant changes
in toxicity proﬁles and treatment effects. An Adaptive Pathway
approach with modiﬁcation of initial basket licensing decisions
grounded on rigorous observation of individual patient experi-
ence may become necessary. Uncertainty associated with long-
term safety and effectiveness of targeted gene therapies and
regenerative medicines has further accentuated the need for
ongoing monitoring of therapies.
Third, payers, providers, and patients seek credible evidence on
the relative effectiveness of new therapies. As the costs of new
therapies continue to rise, demands for evidence-based pricing
and coverage are increasing. Regulatory approval is a necessary
but not sufﬁcient condition for effective patient access. Payer
decisions on the terms of coverage are keys to patient access to a
new therapy, while the price of a therapy affects sponsor incen-
tives for drug development and the willingness of private and
public payers to extend coverage.
Payers are shifting from seeing decisions on reimbursement as
a one-time binary decision, to seeing reimbursement decisions as
an ongoing process aimed at providing greater certainty about
value as evidence accumulates. Once a coverage decision has been
made, payers have an interest in limiting initial use to subpopula-
tions with the most favorable cost-effectiveness ratios, in improv-
ing patient adherence, in monitoring treatment outcomes, and in
modifying conditions of reimbursement in light of RWE on
effectiveness. All of these activities require improved generation
and utilization of data on the safety and effectiveness of drugs in
use.
Patients and providers are demanding more evidence than has
traditionally been available to them. The evidence needed to
inform treatment choices is both difﬁcult to access and interpret.
Furthermore, data are a principal source of inﬂuence in shaping
regulatory licensing decisions and payer reimbursement decisions.
Even when access to raw data is provided, patients and providers
may lack the context-speciﬁc knowledge needed to interpret
information, to combine varied sources of information, and to
generate credible ﬁndings to inform treatment choices and to
inﬂuence regulatory and payer decisions.
ELEMENTS OF NEED FOR EVIDENCE-BASED MEDICINE
The three trends above, taken together, have substantially
increased demand for better understanding of the safety and
effectiveness of drugs in use. The balance of this essay provides
an overview of how those demands may be addressed in a more
coordinated and timely manner, with emphasis on evidence
generation through improved data quality and access; on analyt-
ical methods to enhance the reliability of ﬁndings on real-world
safety and effectiveness under less-than-ideal conditions for
robust causal inference; and on information tools and platforms
to enable more rapid utilization of health data for decision
making.
Data quality: integration and curation
RWE generation is now based on many types of data, including
administrative claims data, electronic medical records, and
patient and product registries. Furthermore, continuous read-
outs from medical instruments, continuous monitoring from
mobile applications, and contextual information from social
media are now available. With the exception of some registries,
these data were not originally created for the evaluation of
safety and effectiveness of drugs, so their value for such second-
ary uses is often unreliable. In addition, they embody varying
degrees of quality, accuracy, and completeness, which adds fur-
ther uncertainty to their utility in the generation of evidence.
The integration of disparate and heterogeneous datasets that
use different diagnostic categories and outcome measures, which
include both genotypic and phenotypic information, and that
are based on different principles of organization, is further a
challenge. For example, acceptable evidence generation and use
requires the ability to understand and adjust for possible bias in
data sources related to such factors as data completeness, data
capture incentives, clinical data workﬂows, and other factors.6–8
Examples of selection biases which may affect data quality are
referral ﬁlter, confounding by indication, and inclusion and
exclusion criteria bias.
Data access: consent and ownership
Access to medical information is now limited by two types of
constraints. Pharmaceutical companies own clinical trials data
and some of the registries, public and private payers own claims
data, and healthcare providers own medical records. Patients, on
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the other hand, have varying degrees of access to their data and
control over the uses of their own genotypic and phenotypic
information. The combination of ownership and consent
requirements presents formidable challenges to the generation of
actionable evidence through the interrogation of disparate and
distributed data sources across organizational boundaries. Fur-
thermore, as the development for smaller subpopulation groups
becomes more prevalent, like for ultra-orphan diseases, the need
to interrogate data across organizational and international boun-
daries will increase. Intellectual property rights conventions,
patient consent, and privacy protections vary markedly from
nation to nation, further complicating effective utilization of
medical data.
Data analysis: analytical methods and research designs to
strengthen causal inference
All methods of evaluating the safety and effectiveness of drugs
have limitations. The classic interventional studies using RCT
provide a valid basis for inferring the safety and efﬁcacy of a drug
for strictly adhering confounder-cleansed populations, but real-
world patient heterogeneity limits the external validity as a basis
for predicting the safety and effectiveness on general populations
with limited adherence. Observational studies based on real-
world data can provide insights into the safety and efﬁcacy of
drugs, but the presence of selection effects, biases in data capture,
and variable data completeness limit the internal validity of such
studies. The issue is not to choose between interventional and
observational studies, but rather to combine appropriate study
designs for RCTs, observational studies, and pragmatic trials
to accelerate evidence generation in a mathematically sound,
statistically robust manner. This integrated evidence generation
approach will accelerate delivery of targeted treatments to
patients in need while simultaneously improving our understand-
ings of safety, efﬁcacy, and effectiveness. One critical operational
issue reduces to the ability to work backwards from observational
studies that may suggest safety problems or effectiveness issues to
the deﬁnition of additional interventional studies.
STATE OF THE ART IN CURRENT DATA INITIATIVES
There are many data initiatives under way in the US and EU
with varying approaches to addressing problems of data quality,
data access, and analytical methods. Table 1 provides an illustra-
tive sample of data initiatives from the public sector, foundations,
and professional societies, with information on lifespan stage,
data types, target outputs, and regional emphasis. Some initiatives
focus explicitly and narrowly on data quality. Clinical Data Inter-
change Standards Consortium (CDISC) and Public Health Data
Standards Consortium (PHDC) focus on fostering data exchange
standards in drug development and medical care delivery phases
to improve interoperability, while the Quality Metrics initiative
by the International Society for Pharmaceutical Engineering
emphasizes standards for quality in discovery and development
phases. Some established initiatives are engaging with data access,
with goals, varying from an emphasis on the safety and effective-
ness in oncology, as in ASCO’s CancerLinQ, to consideration of
safety across many indications, as in ENCePP and the Sentinel.
The Innovative Medicines Initiative (IMI) in the EU is now sup-
porting projects that will foster shared data access and the
advancement of methods suited to improving understandings of
the safety and effectiveness of drugs.
To anchor discussion of data quality, data access, and analytical
methods, two examples involving different but potentially com-
plementary data systems in the US are provided, each with its
own distinctive architecture and mode of ownership. These
include: the Sentinel Initiative, a public, distributed system, and
Optum Labs, a private, centralized system. Both the Sentinel and
Optum Labs are established initiatives with sufﬁcient time-in-use
to provide a practical basis for discussion.
Sentinel Initiative: a distributed data system9
The US Food and Drug Administration (FDA) created the
Sentinel Initiative in response to a congressional mandate to
enhance active postmarket surveillance for drugs. As part of the
Sentinel Initiative, the FDA created the Mini-Sentinel project
(now transitioning to “Sentinel”) and the Mini-Sentinel opera-
tion center that coordinates data analysis, data-partner manage-
ment, and distributed querying and analysis. The distributed
nature of the network means that the data partners maintain
control of their data behind their ﬁrewalls, and respond to
queries sent by the operations center. The operations center col-
laborates with data partners to design algorithms and write dis-
tributed analytic code (in SAS) to be run by data partners. The
Sentinel operations center sends out code to partners, partners
run the code on their data, and partners send results of the anal-
ysis back to the Sentinel. As a matter of policy, Sentinel wants
to bring as little data as possible from its data partners. The
FDA covers the annual cost of around $14 million to maintain
the data network as well as to support the operation center,
maintenance of the data network, and query-related costs.10
The network data partners in the Sentinel Initiative together
maintain in a common data model electronic health data for
more than 178 million US lives. The data include health insur-
ance administrative and claims data coupled with clinical infor-
mation for a subset of patients.11
Standards. Once SAS code is generated, no changes can be made
by the user. The operations center develops, and data partners
implement, the SAS programs. This is an example of standar-
dized analytics, where the code is not changed for different data
sources.12 The analytics uses a common data model that leverages
existing data standards commonly used by health insurers and
clinical practices in the US (e.g., International Classiﬁcation of
Diseases, Clinical Modiﬁcation [ICD-9-CM], American Medical
Association’s Current Procedural Terminology [CPT] codes, and
National Drug codes [NDC]). Insurance companies or data part-
ners maintain the patient-level data per the industry standards.
Without access to patient-level data, Sentinel can identify poten-
tial biases and errors in the aggregate by comparing results across
sources but data curation remains the responsibility of data
partners.
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Ownership. The Sentinel is a distributed data network, and, as
such, the FDA does not collect any data itself. Data partners use
data routinely collected for administrative, billing, and clinical
care purposes. The data partners are responsible for the protec-
tion and appropriate use of the data. The data partners can opt-
in for any queries initiated by the FDA.
Privacy and consent. Currently, only the FDA may initiate
queries in Sentinel. Institutional Review Board (IRB) approvals
are not required for FDA queries initiated to protect public
health. Sentinel is part of a program of active surveillance for
adverse effects of drugs, and as such, this provides the legal foun-
dation for treatment of queries under a public health exception
doctrine. Data partners can use their data as they wish, but must
secure approval for research from IRBs with customary provisions
for informed consent. For example, Aetna, a data partner for the
Sentinel, complies with the provisions of the Health Insurance
Portability and Accountability Act of 1996 (HIPAA)13 for
operations-related research using patient-level data.
Analytical methods. The reliance on a distributed structure, with
queries to data owners returning marginal counts or intermediate
matrices rather than individual-level data, complicates the use of
advanced analytical methods to control for selection effects and
interaction effects, limits data curation, precludes follow-up
queries for further information on individual cases. The infer-
ence, however, is limited for small population indications, in cases
when only the pooling of data from each partner would provide
adequate statistical power to the analysis. At the same time, the
distributed architecture is the key to providing Sentinel access to
a very large and heterogeneous set of data sources.
Optum Labs, a centralized data system14
Optum Labs, an afﬁliate of UnitedHealth Group, is the ﬁrst of
its kind of an open, collaborative research and innovation center
designed to harness RWE. A key asset of Optum Labs is a rich,
high-quality, integrated healthcare database, covering more than
150 million US lives with deidentiﬁed claims and clinical data
from multiple health plans and provider groups. The data are
integrated across care settings and longitudinally linked at the
patient level. The database scale supports identiﬁcation and sizing
of important subgroups and rare occurrences.
The data are assimilated and stored in a secure central location,
rather than being held at their contributing sources, as in a distrib-
uted approach. The centralized data facilitate rapid turnaround on
analyses, and enables close investigation of rare events, small
patient subgroups, and other important inquiries that are difﬁcult
to conduct with a distributed data model. The centralized model
also facilitates direct queries of the full database to test project fea-
sibility and generate preliminary descriptive results without need-
ing to distribute common protocols to remote data holders, obtain
iterative approvals, and aggregate results across sites postanalysis.
Standards. All claims data from the contributing plans are stored
in a common data model and subjected to numerous edit checks
to cleanse the data to support research. The same is true of the
EMR data contributed by providers. However, in the case of the
EMR data up to 85% of the clinical content originally resides in
unstructured data. As a consequence, thousands of clinical data
elements are extracted from EMRs through natural language
processing (NLP), curated, normalized, and then linked to claims
at an individual level to add great clinical depth to the claims
population breadth.
Ownership. As with Sentinel, Optum Labs utilizes data routinely
collected for administrative, billing, and clinical care purposes.
Data rights to use deidentiﬁed claims and EMR data for research
is obtained by Optum Labs from the contributing health plans
and provider groups under its business associate relationships
with these organizations. This enables the use of a centralized
data system with signiﬁcant beneﬁts as noted below.
Privacy and consent. Only deidentiﬁed patient data are held by
Optum Labs and used for research. The patient-protected health
information is encrypted and double-hashed into unique identi-
ﬁers that enable data to be linked across sources in a completely
deidentiﬁed manner. Research enclaves are established for each
research project. Data views are prepared for researchers that con-
tain data elements required for their research problem. A statisti-
cal expert in deidentiﬁcation approves all views and determines
that the data elements in combination present a “very small” risk
of reidentiﬁcation, as speciﬁed by HIPAA.
Analytical methods. The reliance on a centralized structure, with
direct access to anonymized individual data, permits the use of
advanced analytical methods to control for selection effects and
interaction effects and allows follow-up queries for further infor-
mation on individual cases. At the same time, the centralized
architecture limits Optum Labs access to a smaller set of data
sources than Sentinel. Sentinel has access to larger claims data,
whereas the scale of the linked clinical and claims data is larger in
Optum Labs.
Extensions and alternatives
The strengths and weakness of Sentinel and Optum Labs are
intrinsically related to the characteristics of distributed public
and centralized private data models.
According to the Center of Biomedical Innovation at Massa-
chusetts Institute of Technology (MIT), there is interest among
global government agencies and foundations focused on biomedi-
cal innovation in the US, EU, Canada, and Asia for the potential
global scale-up of the Sentinel model (unpublished survey). In
addition, there is interest among payers and pharmaceutical com-
panies to explore the use of the Sentinel model to answer both
safety and effectiveness-related questions.15 It is unclear if such
work would require IRB approval as queries move beyond areas
covered by the current public health exemption. Problems of data
curation and causal inference as noted above would remain chal-
lenging for the use of a distributed data system to reach conclu-
sions on effectiveness.
A broader version of the private centralized approach modeled
after Optum Labs could be viable, with other private and public
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healthcare networks nucleating around the Optum Labs network
or forming on their own. By pooling individual-level information
from multiple sources, such an expanded private network would
have advantages in terms of inferring safety and effectiveness of
drugs targeted at small populations and detect potential system-
atic biases in data sources. Most signiﬁcantly, deanonymized indi-
vidual level data could be used to detect and correct errors in
databases and to test hypotheses from observational data by set-
ting up focused interventions and pragmatic clinical trials.
Although deanonymization of data provides potential for addi-
tional insights, it needs to balance the privacy requirements as
speciﬁed by HIPAA.
Product, patient, disease, and treatment-speciﬁc registries pro-
vide an alternative to general distributed and centralized data
models. In fact, sponsors and regulators are increasingly turning
to product registries to address the immediate need for control
over the quality of the data on the safety and efﬁcacy of each
product. Over time, though, the lack of interoperability of these
registries will likely slow the evolution of knowledge about the
disease at the individual and population levels due to the frag-
mentation of associated information. A carefully curated registry
has clear advantages relative to general-purpose distributed and
centralized data initiatives. However, registries do not eliminate
the need for more general purpose data initiatives. First, product-
speciﬁc registries do not address payer demands for comparative
effectiveness data on a product and on alternative therapies. Sec-
ond, developing product-speciﬁc evidence may require linking
multiple registries, each of which captures data on narrow subpo-
pulation; e.g., regenerative medicines are typically variations on a
technology platform with slight modiﬁcation for different indica-
tions requiring separate registries. Third, given speciﬁc enroll-
ment criteria and sponsorship of registries, inclusion and
exclusion biases are common, and generalizability is often prob-
lematic. Some combination of more targeted registries and
general-purpose data initiatives may be needed to generate high-
quality generalizable data at reasonable cost.
Various emerging software companies, like Aetion Inc., have
developed tools to address the growing need for increased speed
of evidence generation particularly using real-world data. These
rapid-cycle analytic tools could be consistently applied to differ-
ent populations or data sources (including the sources noted
above), on a pooled- or source-by-source basis, which may help
provide better understanding of the variations of treatment
effects while using standardized analytics. Such tools can reduce
the time to conduct epidemiological and cost-effectiveness
research using large real-world datasets.
CONCLUSIONS: RECOMMENDED RESEARCH TOPICS AND
POLICY AGENDAS
Research topics and policy agendas are typically decoupled, to be
addressed by technical and policy experts working in separate
spheres. Academic research topics focus on improving data qual-
ity and access and on developing hybrid observational and inter-
ventionist methods to enhance causal inference under less-than-
ideal conditions. Policy agendas focus on the need for interna-
tional coordination on data access, data standards, and evidenti-
ary thresholds. These spheres are in fact connected. Failures in
the realm of policy coordination and standard setting may under-
score the need for development of technical methods for dealing
with nonstandardized data, while successes may ease technical
challenges. Conversely, technical work on estimation of biases in
data may inform the policy problem of setting of evidentiary
standards and thresholds.
Data quality
Existing data initiatives such as CDISC have rightly focused on
the problems of data standardization and interoperability. The
curation of heterogeneous datasets is an under-researched topic. At
the most basic level, detecting and correcting for simple measure-
ment and data entry errors is a challenge. Developing and improv-
ing analytical tools for recognition of inconsistent values and
development of better testing of the ﬁdelity of existing and emerg-
ing analytical methods will be an important contribution. At a
more advanced level, all data sources have some elements of bias.
Understanding and explaining the speciﬁc types of bias is impor-
tant for developing and communicating RWE. For example, evalu-
ating and adjusting for possible biases in diagnostic codes in claims
data will be difﬁcult. One idea for estimating biases in claims data
entails exploiting natural experiments, where the strength of biases
may be expected to differ. For example, in Singapore reimburse-
ment for drug costs is done from medical savings accounts without
ﬁxed formularies. This weakens incentives for physicians to shade
diagnostics codes to justify patient reimbursements. Statistically
controlled comparisons of diagnoses and prescriptions in Singapore
with diagnoses and prescriptions in healthcare systems with con-
ventional formularies, like the US, may provide a basis for better
estimating biases in diagnostic codes and in calculating rates of off-
label use. These examples are illustrative, and extended brainstorm-
ing focused on these topics would be fruitful.
Data access
The Sentinel Initiative and Optum Labs overcame data access prob-
lems using different approaches. It is important to conduct analysis
of intellectual property rights and privacy/informed consent
requirements in consultation with specialists on those issues. Data
ownership and access rules vary markedly even within OECD
nations, with US and EU differences on public access to trials data
and with substantial variation in protections for genomic and phe-
notypic information. An important issue for consideration, particu-
larly in the context of the potential extension and/or scale-up of
the Sentinel Initiative beyond its piloted use in addressing safety
queries posed by the FDA, is the distinction between public health
and research topics that serves public interests. In addition, it would
be valuable to analyze alternative methods of deﬁning and securing
consent for utilization of linked genotypic and phenotypic informa-
tion. And ﬁnally, a systematic analysis of differences between
OECD and non-OECD nations would be useful in a world of glo-
balized drug development, production, and distribution.
Analytical methods
Rather than recapitulating conventional debates on the relative
merits of RCTs vs. observational data, researchers should focus on
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how observational and experimental methods could be leveraged in
a complementary way to improve inferential validity. Speciﬁcally,
how the integration of evidence using RCTs, observational studies,
and pragmatic trials in an unconventional order could accelerate
the delivery of targeted treatments to patients in need, while simul-
taneously improving our understandings of safety and efﬁcacy. For
example, observational methods might generate suggestive results
on comparative effectiveness, with reservations based on the possi-
ble existence of selection biases. The random assignment of
patients to treatment groups in a pragmatic trial could resolve
uncertainty over observational results.
Policy coordination and standardization
Moving beyond research, progress in the generation and utiliza-
tion of RWE would be fostered by international coordination on
data curation and interoperability standards, intellectual property
rights, subject patient consent, and evidentiary thresholds. Many
public–private initiatives to explore the prospects for coordina-
tion on these issues are under way globally (Table 1), but inte-
grating the insights and outputs from these efforts into practice
will be challenging. Ultimately, standards are needed to clarify
the requirements for acceptability by the key decision-makers.
Elements of these standards are beginning to evolve in the US16
and EU.17 However, using the evolutionary timeline of nearly 60
years so far for Good Clinical Practice (GCP) guidelines as a
benchmark,18 it will take years for these standards to evolve. In
the meantime, there are immediate actions that can catalyze and
inform the development of standards (Figure 1), particularly
when carried out in the context of collaborative multistakeholder
efforts. For example, in IMI at least two relevant initiatives,
GetReal19 and Big Data for Better Outcomes,20 are starting to
explore the issues related to standards for RWE.
In addition, the MIT New Drug Development Paradigms
(NEWDIGS) initiative’s Data Program was launched in 2014 to
provide an integrative test-bed environment to catalyze coordi-
nated progress in this area. Structured as a precompetitive multi-
stakeholder collaboration, and leveraging the systems engineering
expertise of MIT, NEWDIGS is committed to building on the
foundation it laid in its work on Adaptive Pathways that inspired
the EMA pilot project launched in March 2014,1,2,21 in order to
address this critical set of innovation enablers. NEWDIGS uses a
case-based collaborative learning and innovation methodology
that proved valuable in its early work on Adaptive Pathways.22
These conﬁdential discussions happen in a safe haven environ-
ment, under the Chatham House rule,23 which enhances candid
dialog and sharing of proprietary data. Moving forward, this
“scenario design” methodology, supported by an evolving open
access modeling and simulation platform,24 will be applied to
explore case-based decision qualiﬁcation criteria for RWE. In
addition, the implications of these options for each stakeholder
and for global health will be assessed.
The pace of change in the generation and exploitation of data on
the real-world effects of drugs will be affected by the extent of intra-
national, international, and interregional cooperation. National ini-
tiatives in the US and EU are under way. In addition to the
initiatives discussed in Table 1, the FDA just issued a request for a
proposal for source data capture from electronic health records,
using standardized clinical research data.25 The internationalization
of such initiatives is coming. Pooling of data will be useful in assess-
ing the safety and efﬁcacy of a drug targeting a small pool of
Figure 1 Framework for action: evolving pipeline for informing real-world evidence (RWE) standards. The schematic illustrates a framework to catalyze
the generation and utilization of RWE and informing the development of RWE standards. As described in the lighter yellow circles, there are several com-
ponents affecting the quality of the RWE: data quality, data access, and analytical methods (dark yellow circles and rectangles). National and international
coordination of stakeholders is needed to not only improve the quality of RWE, through data curation and interoperability standards, intellectual property
rights, subject patient consent, and evidentiary thresholds, but to agree on how to use RWE by addressing policy, economics, ethics, processes, and legal
issues (blue circle). Insights and outputs from many public–private initiatives to improve the quality of RWE can be integrated by developing a case-based
qualification criteria for RWE acceptable to stakeholders (green circle). This, in turn, will advance the discussion towards acceptable RWE standards by
the key decision-makers (orange circle). The two-sided arrows represent the influence of one on another.
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patients. Pooling of data from ﬁrms or nations with different
degrees of care in limiting off-label uses will be useful in discovering
second and third uses of previously licensed drugs and in identifying
combination therapies. Pooling resources in the development of
analytic methods to make better use of observational data, to over-
come problems with data quality, and to integrate observational
methods and trials may create the tools that will be needed to accel-
erate change in data generation and exploitation.
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